Attached files
file | filename |
---|---|
EXCEL - IDEA: XBRL DOCUMENT - Hubei Minkang Pharmaceutical Ltd. | Financial_Report.xls |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly period ended June 30, 2012
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 000-53231
HUBEI MINKANG PHARMACEUTICAL LTD.
(Exact name of registrant as specified in its charter)
Nevada
|
26-24106855
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
55 Ubi Ave. 3, #03-01, Mintwell Building, Singapore
|
408864
|
|
(Address of principal executive offices)
|
(Zip Code)
|
+65-6747-7883
|
Registrant’s telephone number, including area code
|
N/A
|
(Former name, former address and former fiscal year, if changed since last report)
|
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T(Section 232.405 of this chapter) during the preceding 12 months(or such shorter period that the registrant was required to submit and post such files. Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “small reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer o Accelerated filer o
Non-accelerated filer o (Do not check if a smaller reporting company) Smaller reporting company þ
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes o No þ
State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date. 44,177,439 shares of common stock as of August 3, 2012.
Explanatory Note
The purpose of this Amendment No. 1 to Hubei Minkang Pharmaceutical Ltd. Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2012, filed with the Securities and Exchange Commission on August 20, 2012 (the “Form 10-Q”), is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language).
No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.
Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
Item 6.
|
Exhibits
|
|
31.1* |
Certification of CEO pursuant to Sec. 302
|
|
31.2* |
Certification of CFO pursuant to Sec. 302
|
|
32.1* |
Certification of CEO/CFO pursuant to Sec. 906
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.INS
|
XBRL Instance Document
|
|
101SCH
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
_________
* These exhibits were previously included in Hubei Minkang Pharmaceutical Ltd. Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2012, filed with the Securities and Exchange Commission on August 20, 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
HUBEI MINKANG PHARMACEUTICAL LTD.
|
|||
Date: September 11, 2012
|
By:
|
/s/ Lee Tong Tai
|
|
Lee Tong Tai
|
|||
President, Chief Executive Officer and a director
|
|||
(Principal Executive Officer)
|
Date: September 11, 2012
|
By:
|
/s/ Loke Hip Meng
|
|
Loke Hip Meng
|
|||
Chief Financial Officer
|
|||
(Principal Financial Officer and Principal Accounting Officer)
|